BioCardia

BioCardia Liabilities

The The Liabilities of BioCardia (BCDA) as of Nov 20, 2026 is 2.52 M USD. In the previous year, The Liabilities was 2.89 M USD — a change of -12.78% (lower).

Liabilities

2.52 MUSD

YoY

-12.78%

Last updated:

In 2025, BioCardia's total liabilities amounted to 2.52 M USD, a -12.78% difference from the 2.89 M USD total liabilities in the previous year.

The BioCardia Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
2.63 M USD
Jan 1, 2019
5.31 M USD
Jan 1, 2020
4.25 M USD
Jan 1, 2021
5.34 M USD
Jan 1, 2022
4.90 M USD
Jan 1, 2023
4.59 M USD
Jan 1, 2024
2.89 M USD
Jan 1, 2025
2.52 M USD
The BioCardia Liabilities history
YEARLiabilitiesYoY
2.52 MUSD-12.78%
2.89 MUSD-37.10%
4.59 MUSD-6.35%
4.90 MUSD-8.27%
5.34 MUSD+25.78%
4.25 MUSD-19.97%
5.31 MUSD+102.21%
2.63 MUSD+8.79%
2.41 MUSD+60.87%
1.50 MUSD+14,900.00%
10,000.00USD+900.00%
1,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioCardia Stock analysis

What does BioCardia do? BioCardia, Inc. generates revenue through its clinical-stage regenerative medicine portfolio, primarily focused on CardiAMP and CardiALLO cell therapies. The CardiAMP Cell Therapy System is in Phase III trials for ischemic systolic heart failure, targeting healthcare providers and clinical trial sponsors seeking advanced treatments for heart failure patients. CardiALLO, an allogeneic off-the-shelf mesenchymal stem cell product, is developed for broader therapeutic applications, appealing to hospitals and research institutions requiring ready-to-use regenerative solutions. The company also monetizes the Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products, which serve as complementary tools for medical professionals during therapeutic procedures. CardiAMP and CardiALLO are positioned as innovative therapeutic candidates targeting heart failure and regenerative medicine segments, with CardiAMP advancing toward potential commercialization in late-stage trials. The Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products cater to interventional cardiology and surgical markets, providing specialized equipment for clinicians. BioCardia's revenue streams are derived from partnerships with clinical trial sponsors and direct sales of medical devices to healthcare facilities, focusing on cardiovascular and regenerative medicine applications. The company's business model relies on developing and commercializing cell therapies and medical devices, with CardiAMP leading the portfolio in late-stage development. CardiALLO serves as a complementary allogeneic product, while the Helix and Morph products support procedural needs in cardiology. Revenue is anticipated from future commercialization of CardiAMP post-trial success and from ongoing sales of the Helix and Morph systems to medical institutions. BioCardia is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing BioCardia's Liabilities

BioCardia's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating BioCardia's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing BioCardia's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

BioCardia's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in BioCardia’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about BioCardia stock

The Liabilities of BioCardia is 2.52 M USD in 2025.

The Liabilities of BioCardia changed from 2.89 M USD to 2.52 M USD, representing a -12.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities BioCardia since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's BioCardia historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioCardia

All Key Metrics — BioCardia